−2.25USD
−62.72 MUSD
21.10 M
About NextCure, Inc.
Sector
CEO
Michael S. Richman
Headquarters
Beltsville
Website
Employees (FY)
82
Founded
2015
ISIN
US65343E1082
FIGI
BBG00BTH5153
NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.
Closing the Gap: NXTC breakoutHi mates there is my another swingtrade.After huge selloff this year, NXTC is in pretty strong uptrend on daily now. There is gap topping 17.55. I expect momentum breakout in few days.
here is data for my trade:
------------------------Trade setup ---------------------------
Entry: 13.60
Stop Loss:
$NXTC NextCure Inc increasingly Bullish Setup Developing
Alert set for break above local downtrend resistance.
Gap fill resistance and Pivot Point is first major target @ $12.97
Volume is bullish and Fridays candle is very encouraging.
RSI MACD & histogram in bullish Trajectory.
Strong bounce off the 50ma.
Alternative is to set alert on the gap fill f
$NXTC NextCure Inc On Breakout Watchlist
Speculative BIO stock with the potential for a breakout in the coming days.
Alerts et for break above downtrend.
Stochastic bottomed and reversing bullishly.
Moving averages reclaimed as support.
RSi just moved above mid-point.
MACD reversal, crossover imminent.
Needs a spike in volume.
NXTC BullishThe chart looks bullish after consolidating since mid July. The MACD crossed a few days ago and the stock broke out of the descending trend lines. First target 12.81
Large CME gap buy option calls for $17An overwhelming percent of the time stocks fill gaps, facts of life.. This one’s got a big gap as noticeable as if bugs bunny would be missing his two front teeth..
Consolidation doesn’t usually last for very long the stock is very much oversold as shown clearly in the chart you can choose to eith
Severely oversold $NXTC #LongWay over sold imo - interesting setup.
This is incredibly oversold easy target of $20. Get long just a beautiful setup.
The sales Q/Q are +1,549.10% (Bullish)
EPS Q/Q +218.20% (Bullish)
Profit Margin is -65% (Very Bearish)
Debt/Eq 0.01 (Bullish)
Current Ratio 40.10 (this is good)
P/B (0.77) (Bulli
Extremely oversold - great long opportunity $NXTC #NextCureNextCure is an easy long right now as it is extremely oversold. Price target would be so in the money, could ride out a chunk of the position. Recommend adding to watchlist.
Updated EW count for NXTCpretty weak bounce off 38.2 retracement that I was expecting. Most likely this is a correction of a correction. Should get a deeper retracement to 68 percene.t
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of NXTC is 1.60 USD — it has increased by 1.59% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange NextCure, Inc. stocks are traded under the ticker NXTC.
NextCure, Inc. is going to release the next earnings report on May 2, 2024. Keep track of upcoming events with our Earnings Calendar.
NXTC stock is 10.52% volatile and has beta coefficient of 1.61. Check out the list of the most volatile stocks — is NextCure, Inc. there?
One year price forecast for NextCure, Inc. has a max estimate of 8.00 USD and a min estimate of 3.00 USD.
NXTC earnings for the last quarter are −0.51 USD per share, whereas the estimation was −0.66 USD resulting in a 22.43% surprise. The estimated earnings for the next quarter are −0.54 USD per share. See more details about NextCure, Inc. earnings.
NextCure, Inc. revenue for the last quarter amounts to 2.00 M USD despite the estimated figure of 534.17 K USD. In the next quarter revenue is expected to reach 6.57 M USD.
Yes, you can track NextCure, Inc. financials in yearly and quarterly reports right on TradingView.
NXTC stock has fallen by 17.78% compared to the previous week, the month change is a 9.44% rise, over the last year NextCure, Inc. has showed a 2.24% increase.
NXTC net income for the last quarter is −14.47 M USD, while the quarter before that showed −14.30 M USD of net income which accounts for −1.16% change. Track more NextCure, Inc. financial stats to get the full picture.
Today NextCure, Inc. has the market capitalization of 43.81 M, it has decreased by 17.67% over the last week.
No, NXTC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, NXTC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NextCure, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 82.00 employees. See our rating of the largest employees — is NextCure, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NextCure, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NextCure, Inc. stock shows the sell signal. See more of NextCure, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on NextCure, Inc. future price: according to them, NXTC price has a max estimate of 8.00 USD and a min estimate of 3.00 USD. Read a more detailed NextCure, Inc. forecast: see what analysts think of NextCure, Inc. and suggest that you do with its stocks.